Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876959 | 1.00 | CTSK (0.58) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL1699915 | 0.94 | CTSK (0.61) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL1808105 | 0.94 | CTSK (0.61) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL1699916 | 0.94 | CTSK (0.61) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL803320 | 0.91 | CTSK (0.58) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL542675 | 0.91 | OPRM1 (0.55) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL23952394 | 0.90 | CA1 (0.59) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL23952393 | 0.90 | CA1 (0.59) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL3440554 | 0.89 | CTSK (0.56) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL2012184 | 0.89 | CTSK (0.56) | CTSKCA1CA2HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960381-B1 | AMINOPHENYLSULFONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITOR | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| US-7803836-B2 | Aminophenylsulfonamide derivatives as HIV protease inhibitor | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-09-28 | — | — | US | disclosed |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | DNPEP, NPEPPS, ANPEP | CTSK 82/4885CA1 4453/4885CA2 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.